Clinical trial
A Phase 1 Study of SG301 in Subjects With Hematological Malignancies
NCT04684108 is registered in ClinicalTrials.gov with Hangzhou Sumgen Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of SG301 in Subjects With Hematological Malignancies
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- November 4, 2021
- Completion date
- December 30, 2026
- Enrollment
- 61 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
hematological malignancy, relapsed or refractory multiple myeloma